Total Payments
$5,501
2024 Payments
$629.74
Companies
31
Transactions
168
Medicare Patients
6,940
Medicare Billing
$814,301
Payment Breakdown by Category
Food & Beverage$4,786 (87.0%)
Travel$702.51 (12.8%)
Education$12.16 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,786 | 164 | 87.0% |
| Travel and Lodging | $702.51 | 3 | 12.8% |
| Education | $12.16 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,287 | 62 | $0 (2024) |
| Alphatec Spine, Inc | $981.88 | 5 | $0 (2021) |
| Stryker Corporation | $456.03 | 5 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $253.46 | 23 | $0 (2018) |
| Allergan, Inc. | $252.79 | 11 | $0 (2020) |
| Abbott Laboratories | $190.80 | 1 | $0 (2023) |
| ACADIA Pharmaceuticals Inc | $170.73 | 5 | $0 (2022) |
| Lilly USA, LLC | $167.66 | 6 | $0 (2024) |
| Biogen, Inc. | $166.89 | 8 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $155.90 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $629.74 | 31 | ABBVIE INC. ($502.33) |
| 2023 | $857.11 | 22 | AbbVie Inc. ($308.01) |
| 2022 | $422.44 | 19 | ABBVIE INC. ($202.00) |
| 2021 | $590.90 | 20 | AbbVie Inc. ($258.82) |
| 2020 | $561.86 | 26 | Allergan, Inc. ($156.74) |
| 2019 | $306.46 | 5 | Covidien LP ($103.06) |
| 2018 | $1,693 | 33 | Alphatec Spine, Inc ($652.12) |
| 2017 | $439.65 | 12 | NUVASIVE, INC. ($122.84) |
All Payment Transactions
168 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: Musculoskeletal | ||||||
| 12/06/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: NEUROSCIENCE | ||||||
| 10/16/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: NEUROSCIENCE | ||||||
| 09/25/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Neurology | ||||||
| 09/13/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: NEUROSCIENCE | ||||||
| 09/11/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: NEUROSCIENCE | ||||||
| 08/26/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $21.15 | General |
| Category: Neuroscience | ||||||
| 08/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/14/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: NEUROSCIENCE | ||||||
| 08/07/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: NEUROSCIENCE | ||||||
| 07/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $25.23 | General |
| Category: NEUROSCIENCE | ||||||
| 06/04/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: AMANTADINE | ||||||
| 05/29/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: Neuroscience | ||||||
| 05/15/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/08/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: NEUROSCIENCE | ||||||
| 05/01/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: NEUROSCIENCE | ||||||
| 04/24/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: NEUROSCIENCE | ||||||
| 04/17/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $32.05 | General |
| Category: NEUROSCIENCE | ||||||
| 03/19/2024 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: NEUROLOGY | ||||||
| 03/15/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/06/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,556 | 2,227 | $352,554 | $185,616 |
| 2022 | 14 | 1,706 | 7,676 | $416,523 | $229,232 |
| 2021 | 13 | 1,854 | 2,564 | $349,027 | $217,824 |
| 2020 | 12 | 1,824 | 2,424 | $321,673 | $181,629 |
Total Patients
6,940
Total Services
14,891
Medicare Billing
$814,301
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 660 | 1,113 | $133,560 | $89,863 | 67.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 123 | 257 | $30,840 | $15,343 | 49.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 140 | 140 | $49,000 | $15,320 | 31.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 110 | 117 | $40,950 | $14,977 | 36.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 203 | 238 | $21,420 | $13,805 | 64.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 66 | 66 | $25,080 | $10,484 | 41.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 63 | 63 | $10,710 | $7,375 | 68.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 41 | 70 | $11,900 | $5,356 | 45.0% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 17 | 17 | $10,200 | $3,556 | 34.9% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 30 | 30 | $4,500 | $3,283 | 73.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 23 | $3,680 | $2,072 | 56.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 29 | 41 | $3,690 | $1,530 | 41.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 21 | 22 | $3,256 | $992.20 | 30.5% |
| 95908 | Nerve conduction, 3-4 studies | Office | 2023 | 13 | 13 | $1,235 | $893.76 | 72.4% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 17 | 17 | $2,533 | $766.70 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 741 | 1,298 | $155,760 | $105,891 | 68.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 207 | 207 | $55,460 | $23,734 | 42.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 12 | 5,225 | $52,250 | $21,076 | 40.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 125 | 128 | $39,850 | $19,116 | 48.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 200 | 234 | $21,060 | $13,022 | 61.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 128 | 239 | $28,680 | $12,935 | 45.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 68 | 76 | $12,920 | $9,673 | 74.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 61 | 105 | $17,850 | $8,203 | 46.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 35 | 35 | $11,790 | $5,770 | 48.9% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 37 | 37 | $5,550 | $3,876 | 69.8% |
About Dr. Paramjit Singh, MD
Dr. Paramjit Singh, MD is a Behavioral Neurology & Neuropsychiatry healthcare provider based in Chico, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740392133.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paramjit Singh, MD has received a total of $5,501 in payments from pharmaceutical and medical device companies, with $629.74 received in 2024. These payments were reported across 168 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($4,786).
As a Medicare-enrolled provider, Singh has provided services to 6,940 Medicare beneficiaries, totaling 14,891 services with total Medicare billing of $814,301. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Behavioral Neurology & Neuropsychiatry
- Location Chico, CA
- Active Since 08/31/2006
- Last Updated 11/15/2017
- Taxonomy Code 2084B0040X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1740392133
Products in Payments
- UBRELVY (Drug) $852.85
- Multiple Products (Device) $652.12
- QULIPTA (Drug) $520.99
- SERRATO (Device) $327.81
- APTIOM (Drug) $253.46
- IdentiTi (Device) $222.45
- PENTA (Device) $190.80
- NUPLAZID (Drug) $170.73
- INGREZZA (Drug) $155.90
- GORE CARDIOFORM Septal Occluder (Device) $147.99
- Aimovig (Biological) $143.79
- TYSABRI (Biological) $130.30
- ACCULIF (Device) $128.22
- GOCOVRI (Drug) $127.63
- RYTARY (Drug) $116.72
- Other - Miscellaneous (Device) $107.31
- BOTOX (Drug) $96.05
- NEURACEQ (Drug) $85.24
- Non-Covered Product (Drug) $73.22
- LEGEND (Device) $57.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.